Brossier 2010

Study characteristics
Patient sampling	Case-control design with unknown mechanism of enrolment of participants, prospective data collection
Patient characteristics and setting	Country of origin: France World Bank classification of country: high Type of lab: reference Type of patients: confirmed MDR-TB cases, confirmed XDR-TB cases, confirmed DS-TB patients
Index tests	Manufacturer involvement: no Type of testing: indirect
Target condition and reference standard(s)	Culture (Solid; agar proportion method on LJ) and sequencing used for FQ, SLID FQ drugs: ofloxacin (2 µg/mL) SLIDs: amikacin (20 µg/mL), kanamycin (20 µg/mL), capreomycin (20 µg/mL) Genes sequenced for FQ: gyrA and gyrB Genes sequenced for SLIDs: rrs Discrepant analysis: no
Flow and timing	Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled?	Yes
Was a case-control design avoided?	No
Did the study avoid inappropriate exclusions?	No
			High
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear
If a threshold was used, was it pre-specified?	Yes
			Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear
			Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Yes